TCT 2021 | iFR-SWEDEHEART: 5 Years to Trust FFR Is Equivalent to iFR

The 5-year followup of the iFR-SWEDEHEART has confirmed the safety and efficacy of using either FFR or iFR to guide PCI in intermediate lesions. 

TCT 2021 | iFR-SWEDEHEART: 5 años para confiar en la equivalencia entre FFR e iFR

The iFR-SWEDEHEART initial outcomes together with the DEFINE-FLAIR outcomes had started the debate around these two measuring strategies. The FFR requires adenosine, which results costly in addition to causing adverse events, while the iFR, measured in the diastolic wave free period, does not require hyperemia. 

One-year outcomes had shown the non-inferiority of iFR, which had been seen by the vast majority in the community as an advantage of physiological assessments in general, vs. the superiority of one technique over the other. 

The 5-year followup was interesting because the iFR arm had included more deferred lesions. There was 29.1% of functionally significant lesion in the iFR arm, while the FFR are had 36.8% (p<0.0001). Fewer treated lesions translated into fewer stenting with iFR.


Read also: TCT 2021 | SUGAR Trial: Polymer-Free Stent in Diabetes.


At 5 years, the combined events rate was 21.5% for iFR vs 19.9% for FFR, a non-significant difference. The subgroup analysis did not hold surprises with the same results in the general population. 

Original Title: iFR-SWEDEHEART: Five-year outcomes of a randomized trial of iFR-guided vs. FFR-guided PCI.

Reference: Götberg M. et al. Presentado en el congreso TCT 2021.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...